Inventor · disambiguated record
Maxwell D. Cummings
Also filed as: CUMMINGS MAXWELL D · CUMMINGS MAXWELL DAVID
31 granted patents·14 pending applications·179 citations·filing 2001–2022
96Inventor score
Files withJANSSEN PHARMACEUTICA NV18SMITHKLINE BEECHAM CORP13LU TIANBAO4DIMENSIONAL PHARM INC2ORTHO MCNEIL PHARM INC1
Top patents by PatentIndex Score
45 records- 0196US9221804B2Secondary alcohol quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Dec 29, 2015·35 cites·23 claims
- 0292US8030305B2Triazolopyridazines as kinase modulatorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Oct 4, 2011·24 cites·18 claims
- 0390US10954214B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Mar 23, 2021·5 cites·37 claims
- 0490US10369146B2Phenyl linked quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Aug 6, 2019·5 cites·13 claims
- 0589US8173654B2Triazolopyridazine compoundsLU TIANBAO·Filed 2008·Granted May 8, 2012·21 cites·15 claims
- 0688US9284308B2Methylene linked quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Mar 15, 2016·6 cites·21 claims
- 0787US7138530B2Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditionsDIMENSIONAL PHARM INC·Filed 2003·Granted Nov 21, 2006·29 cites·48 claims
- 0885US9328095B2Heteroaryl linked quinolinyl modulators of RORgammatJANSSEN PHARMACEUTICA NV·Filed 2013·Granted May 3, 2016·3 cites·5 claims
- 0984US9403816B2Phenyl linked quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Aug 2, 2016·3 cites·5 claims
- 1084US7405209B2Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2005·Granted Jul 29, 2008·2 cites·16 claims
- 1183US7109354B2Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditionsDIMENSIONAL PHARM INC·Filed 2003·Granted Sep 19, 2006·17 cites·16 claims
- 1280US10888550B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jan 12, 2021·3 cites·10 claims
- 1379US9624225B2Quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Apr 18, 2017·3 cites·10 claims
- 1477US9346782B2Alkyl linked quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2014·Granted May 24, 2016·3 cites·6 claims
- 1577US7662824B2Acylhydrazones as kinase modulatorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Feb 16, 2010·2 cites·12 claims
- 1676US11040031B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jun 22, 2021·2 cites·9 claims
- 1776US7071184B2Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Jul 4, 2006·7 cites·7 claims
- 1876US2024300939A1Urea derivatives which can be used to treat cancerSCORPION THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1968US7067512B2Substituted 1,4-benzodiazepines and uses thereofLU TIANBAO·Filed 2002·Granted Jun 27, 2006·5 cites·33 claims
- 2065US7115598B2Substituted 1,4-diazepines and uses thereofORTHO MCNEIL PHARM INC·Filed 2004·Granted Oct 3, 2006·2 cites·62 claims
- 2164US12077521B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Sep 3, 2024·0 cites·18 claims
- 2263US7456211B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2007·Granted Nov 25, 2008·0 cites·13 claims
- 2362US6897233B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2002·Granted May 24, 2005·2 cites·3 claims
- 2458US7868023B2Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditionsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Jan 11, 2011·0 cites·17 claims
- 2558US2006025412A1Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2005·Application pending·0 cites
- 2656US7563784B2Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2006·Granted Jul 21, 2009·0 cites·7 claims
- 2754US7115605B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2004·Granted Oct 3, 2006·0 cites·16 claims
- 2852US7385066B2Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditionsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Jun 10, 2008·0 cites·12 claims
- 2951US2016136149A1HETEROARYL LINKED QUINOLINYL MODULATORS OF RORytJANSSEN PHARMACEUTICA NV·Filed 2016·Application pending·0 cites
- 3050US6852882B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2002·Granted Feb 8, 2005·0 cites·5 claims
- 3150US2004002487A1Protease inhibitorsFiled 2003·Application pending·0 cites
- 3249US10201546B2Quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Feb 12, 2019·0 cites·18 claims
- 3349US2006235007A1Substituted 1,4-diazepines and uses thereofLU TIANBAO·Filed 2006·Application pending·0 cites
- 3449US2004229863A1Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2004·Application pending·0 cites
- 3548US6806369B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Oct 19, 2004·0 cites·3 claims
- 3648US2006148792A1Substituted 1,4-benzodiazepines and uses thereofLU TIANBAO·Filed 2006·Application pending·0 cites
- 3748US2003225061A1Protease inhibitorsFiled 2003·Application pending·0 cites
- 3847US2003144175A1Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2001·Application pending·0 cites
- 3947US2004097732A1Peptide deformylase inhibitorsFiled 2002·Application pending·0 cites
- 4046US2002147188A1Protease inhibitorsSMITHKLINE BEECHAM CORP·Filed 2002·Application pending·0 cites
- 4145US2004034024A1Peptide deformylase inhibitorsFiled 2001·Application pending·0 cites
- 4245US2004034013A1Methods of treatmentFiled 2001·Application pending·0 cites
- 4343US10555941B2Alkyl linked quinolinyl modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Feb 11, 2020·0 cites·16 claims
- 4443US7375120B2Peptide deformylase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2003·Granted May 20, 2008·0 cites·4 claims
- 4543US2003114437A1Protease inhibitorsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maxwell D. Cummings files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →